EVM
PBYI icon

Eaton Vance Management’s Puma Biotechnology PBYI Stock Holding History

Eaton Vance Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-142,000
Closed -$4.23M – 979
2016
Q2 		$4.23M Buy
+142,000
New +$4.44M 0.01% 443

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Eaton Vance Management's PBYI Position: Q3 2016 in Review

Eaton Vance Management sold out of Puma Biotechnology (PBYI) in Q3 2016, closing a stake of 142,000 shares — an estimated $4.23M sold.

Eaton Vance Management first reported a position in PBYI in Q2 2016 and held it in 1 quarter. The position peaked at $4.23M in Q2 2016. 149 funds tracked by Wall St. Rank hold PBYI as of Q3 2016.

  • Eaton Vance Management reported no remaining Puma Biotechnology position as of Q3 2016 after selling out during the quarter.
  • Eaton Vance Management sold 142,000 Puma Biotechnology shares in Q3 2016, an estimated $4.23M.
  • Eaton Vance Management first reported a position in Puma Biotechnology in Q2 2016 and held it in 1 quarter.
  • Eaton Vance Management's Puma Biotechnology position peaked at $4.23M in Q2 2016.
  • 149 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2016.

Based on Eaton Vance Management's 13F filing for Q3 2016, filed 15 Nov 2016.